

**Louisiana Office of Public Health
Antimicrobial Stewardship Summit
June 17, 2022**

Faculty Disclosure

This activity has been planned and implemented in accordance with the ACCME's Accreditation Requirements and the 2018 IACET Standard to insure balance, independence, objectivity, and scientific rigor. All individuals responsible for content, regardless of role(s), are required to document financial relationships or the absence of relationships with commercial or proprietary interests, and all potential conflicts of interest must be resolved prior to the activity. Disclosure of off-label, experimental or investigational use of drugs or devices must also be made known to the audience. Tulane Center for Continuing Education has also required that all faculty disclose their intent to discuss any unlabeled/unapproved usage of drugs and/or devices during their presentations.

Listed below is information disclosed by presenters. Any real or apparent conflicts of interest related to the content of their presentation have been resolved.

Name	Affiliation/Financial Interest	Organization(s)
Travis King	Speakers Bureau Consultant	Melinta Therapeutics and Gilead Sciences Gilead Sciences and Theratechnologies
Myra Kleinpeter **	Speakers Bureau Stock Options	Gilead Sciences, Fresenius Kidney Care BD, Abbvie, Pfizer, P&G

The following presenters/staff have documented they have nothing to disclose:

Nicole Alilaen	Joanne Maffei
Fatima Brakta*,	Ashley Marin
Gregory Cook	Pamala Schmidt*
Brett Dragomer	Erica Washington*
Grace Lee *	

*Planning Committee

**CME Advisory Committee Chair

Unapproved or Off Label Disclosure

Dr. King has disclosed that his presentation may involve comments or discussion concerning unapproved or off-label uses of Antimicrobials, broadly.

Dr. Maffei has disclosed that her presentation may involve comments or discussion concerning unapproved or off label uses of antifungal combinations for the treatment of systemic candidiasis and vulvovaginal candidiasis.

All other speakers have disclosed that their presentations will not involve comments or discussion concerning unapproved or off-label uses of a medical device or pharmaceuticals.